Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NextMeds vs Reset Solutions

NextMeds
Graded #207

Higher grade

vs+9.899999999999991
Reset Solutions
Graded #420

Lower grade

The verdict

NextMeds takes it — 66.1/100 to 56.2/100.

NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNextMeds +10
55
45
Dose & formulationNextMeds +24
64
40
Clinical oversightReset Solutions +1
77
78
Labs & monitoringEven
61
61
FulfillmentNextMeds +19
84
65
Contract termsNextMeds +6
61
55
NextMeds · left barReset Solutions · right bar

The numbers

MetricNextMedsReset Solutions
WeighScore66.1/10056.2/100
GradeCC
Scorecard rank#207#420
Semaglutide$129/mo (plus a separate fee, compounded)Not disclosed
Tirzepatide$179/mo (plus a separate fee, compounded)Not disclosed
CoverageAll 50 states1 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
NextMeds

Graded #207 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Reset Solutions

Graded #420 · C

Strengths

  • $99/mo program covers all medical visits, coaching, check-ins, and 3D body-composition testing
  • Medication priced separately starting at $70/month - combined from ~$169/mo, under the compounded-sema market median
  • Full refund if the doctor determines you are not a medical candidate
  • No long-term contract - cancel anytime; lower-cost maintenance plan once established
  • Local care team: in-person kickoff, dose adjustments over time, and app messaging

Where it loses points

  • Texas only - requires an in-person kickoff at its Shenandoah (The Woodlands) clinic
  • Medication form (compounded vs brand) is not stated in page copy; per-drug pricing not itemized
  • Tirzepatide cost not published - only 'starting at $70 per month' across medication options
  • Pharmacy partner not publicly named
  • No LegitScript certification displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard